• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Atypical antipsychotics linked with acute kidney injury in the elderly

byKenan Celtik, MSandAimme Li, MD
August 19, 2014
in Chronic Disease, Nephrology, Neurology, Psychiatry
Reading Time: 3 mins read
Pre-operative transcranial magnetic stimulation useful for language mapping
Share on FacebookShare on TwitterShare on LinkedIn

1.   Atypical antipsychotics given to elderly patients in outpatient setting were associated with a 75% increased 90-day risk of hospitalization for acute kidney injury (AKI) when compared to untreated controls.

2.  Older patients taking atypical antipsychotics were nearly twice as likely to develop multiple severe complications, including death. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Atypical antipsychotics including olanzapine, quetiapine, and risperidone are frequently used to manage the behavioral symptoms of dementia in the elderly. The Federal Drug Agency (FDA) has issued a black box warning for these drugs based on 17 trials that demonstrated an increased rate of death in elderly patients with dementia taking these drugs. This population-based retrospective cohort study sought to examine the risk of hospitalization secondary to acute kidney injury (AKI) and other adverse outcomes associated with new oral atypical antipsychotic use in the elderly.  The study included residents of Ontario, Canada aged older than 65 years who received a new prescription for atypical antipsychotics in the non-hospital setting. Patients that received these drugs, when compared to untreated matched controls, were at significantly increased risk of hospitalization for acute kidney injury (AKI).  The results also suggested an association between atypical antipsychotic use and other complications including hypotension, acute urinary retention, pneumonia, acute myocardial infarction and ventricular arrhythmia. Furthermore, subjects that were taking these drugs were over twice as likely to die from any cause during the 90-day follow-up period. A major weakness of this study was the limited study population, as well as the failure to identify and include patients who experienced AKI without hospitalization as a study outcome.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: The Efficacy and Safety of Atypical Antipsychotics for the Treatment of Dementia: A Meta-Analysis of Randomized Placebo-Controlled Trials

RELATED REPORTS

Ibuprofen is associated with acute kidney injury in high-risk inpatients but not low-risk.

FDA Approves First DNA Medicine to Reduce Repeat Airway Surgeries

In-Depth [retrospective cohort]: This study is a population-based retrospective cohort study.  The study included patients from Ontario, Canada aged 65 years and older with outpatient prescribed atypical antipsychotics between 2003 and 2012. The 97,777 patients that were eligible for inclusion in the study were matched by 97,777 controls. Compared to the controls, the cohort of elderly patients on atypical antipsychotics were at significantly increased risk of hospitalization for AKI (RR 1.73, CI 1.55-192), hypotension (RR1.91, CI 1.60-2.28), acute urinary retention (RR 1.98, CI 1.63-2.40), pneumonia (RR 1.50, CI 1.39-1.62), AMI (RR 1.36, CI 1.20-1.53), ventricular arrhythmia (RR 1.47, CI 1.18-1.82) and all-cause mortality (RR 2.23, CI 2.28-2.50). This study demonstrated that severe multisystem complications and reduced survival must be considered when physicians prescribe these medications to manage the behavioral symptoms of dementia.

More from this author: Rituximab not beneficial long-term in Sjorgen’s SyndromeHigh-energy shockwave therapy effective in treating shoulder calcific tendinitisTenofovir prophylaxis linked with reduced risk of herpes simplex 2 

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: acute kidney injuryAntipsychoticFDAOlanzapinequetiapinerisperidone
Previous Post

Social cohesion may reduce heart attack risk

Next Post

Blood clot prophylaxis for medicine inpatients may be unnecessary

RelatedReports

A detailed illustration of a kidney and glomeruli, with a pill depicted, representing treatment for kidney-related conditions. It suggests a focus on chronic kidney disease.
All Specialties

Ibuprofen is associated with acute kidney injury in high-risk inpatients but not low-risk.

November 12, 2026
Collage for HPV: a preteen boy with a small bandage on his arm, a virus particle, a vaccine vial and a school backpack
Infectious Disease

FDA Approves First DNA Medicine to Reduce Repeat Airway Surgeries

November 10, 2026
An illustration depicting the colon with IV bags on either side, symbolizing sequential therapy paths in colorectal cancer treatment.
Gastroenterology

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

October 29, 2026
Variation noted across pre- and post-marketing studies for FDA approved devices
Pharma

FDA warns Novo Nordisk over safety reporting violations

April 6, 2026
Next Post

Blood clot prophylaxis for medicine inpatients may be unnecessary

Oxygen readings sway decision to hospitalize infants with bronchiolitis

Patient-controlled pain meds superior to epidural after laparoscopic surgery

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.